H. Altamura

发表

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

D. White, T. Hughes, C. Kok, 2019, Leukemia.

Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1–PDFGRB fusion gene

H. Scott, A. Schreiber, J. Geoghegan, 2016, Leukemia.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

J. Hodgson, V. Rivera, S. Lustgarten, 2016, Blood.

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Anna L. Brown, Paul P. S. Wang, D. Thomson, 2018, Blood.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Nicola D. Roberts, J. Seymour, T. Hughes, 2014, Blood.

Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript.

S. Branford, H. Altamura, K. Taylor, 2019, Leukemia research.

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Dong-Wook Kim, T. Hughes, S. Branford, 2020, Blood.

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Susan Branford, J. Reynolds, N. Briggs, 2013, Blood.

Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months

Nicola D. Roberts, T. Hughes, D. Yeung, 2013 .

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

Paul P. S. Wang, D. Thomson, H. Scott, 2023, Haematologica.

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML

S. Branford, D. Yeung, Chani R Field, 2012 .